Clinical Trials
PI-2301 is currently in phase Ib development
Peptimmune has initiated a twelve-week phase Ib MS patient study.
PI-2301 is currently in phase Ib development and is a second-generation copolymer for multiple sclerosis (MS), Crohn’s disease, uveitis, and potentially neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). A Phase Ia safety and pharmacokinetic study has been completed, and all doses of PI-2301 have been found to be safe and well tolerated, along with evidence of bioactivity. Peptimmune has initiated a twelve-week phase Ib MS patient study Q2/2008. This study will confirm repeat-dose safety and proof of pharmacologic mechanism for PI-2301. Phase Ib development is being conducted at multiple sites in France.
Please select from the medical condition or product candidate below:
read our patient info in French
read our patient info in English
